MediciNova

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS	Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder	Active, not recruiting	Phase 2 / Phase 3	2026-03-06		NCT04057898
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia	Digestive System Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, hyperlipidemia, hypertriglyceridemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus	Active, not recruiting	Phase 2	2026-02-05		NCT05464784

Clinical trials